SCHEMBL4367747

SCHEMBL4367747

CCNC(=O)c1ccccc1Oc1cccc(C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPK1 P28482 1/20 0.49
GFER P55789 1/20 0.49
ALDH1A1 P00352 5/20 0.49
GAA P10253 4/20 0.49
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
MAPK8 P45983 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HTT P42858 1/20 0.48
ATM Q13315 1/20 0.48
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
HCRTR1 O43613 2/20 0.47
KCNK3 O14649 1/20 0.46
KCNK9 Q9NPC2 1/20 0.46
TSHR P16473 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180616 0.86 L3MBTL1 (0.65) L3MBTL1NPSR1MAPK1ALDH1A1GAA
SCHEMBL29250428 0.80 GAA (0.58) L3MBTL1NPSR1MAPK1GFERALDH1A1
SCHEMBL2867681 0.80 GFER (0.59) MAPK1GFERALDH1A1GAAKDM4E
SCHEMBL15334093 0.79 PTGDR2 (0.53) L3MBTL1NPSR1HPGDHTTRAB9A
SCHEMBL13687512 0.79 CTNNB1 (0.68) L3MBTL1MAPK1GFERALDH1A1GAA
SCHEMBL8948862 0.78 IDO1 (0.51) L3MBTL1MAPK1GFERALDH1A1GAA
SCHEMBL8954770 0.78 GAA (0.51) L3MBTL1MAPK1GFERALDH1A1GAA
SCHEMBL9850074 0.77 CYP2C19 (0.69) MAPK1GFERALDH1A1GAAKDM4E
SCHEMBL27511977 0.76 POLB (0.55) NPSR1MAPK1GFERALDH1A1GAA
SCHEMBL4114974 0.75 CTSD (0.69) MAPK1ALDH1A1GAAHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101445437-B Improved process for the catalytic synthesis of diaryl ethers SALTIGO GMBH 2014-07-02 CN disclosed
EP-2065357-B1 Improved process for the catalytic synthesis of diaryl ethers SALTIGO GMBH (DE) 2014-04-23 EP disclosed
US-8304550-B2 Process for the catalytic synthesis of diaryl ethers SALTIGO GMBH (DE) 2012-11-06 US disclosed
US-20090143594-A1 PROCESS FOR THE CATALYTIC SYNTHESIS OF DIARYL ETHERS SALTIGO GMBH (DE) 2009-06-04 US disclosed
EP-2065356-A1 Improved process for the catalytic synthesis of diaryl ethers Saltigo GmbH (DE) 2009-06-03 EP disclosed
EP-2065357-A1 Improved process for the catalytic synthesis of diaryl ethers Saltigo GmbH (DE) 2009-06-03 EP disclosed
CN-101445437-A Improved process for the catalytic synthesis of diaryl ethers SALTIGO GMBH (DE) 2009-06-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143594-A1 PROCESS FOR THE CATALYTIC SYNTHESIS OF DIARYL ETHERS ARSA, AHR, AOC2 L3MBTL1 4811/4885NPSR1 1831/4885MAPK1 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.